SG11202108940RA - Novel heterotricyclic derivative compound and use of same - Google Patents
Novel heterotricyclic derivative compound and use of sameInfo
- Publication number
- SG11202108940RA SG11202108940RA SG11202108940RA SG11202108940RA SG11202108940RA SG 11202108940R A SG11202108940R A SG 11202108940RA SG 11202108940R A SG11202108940R A SG 11202108940RA SG 11202108940R A SG11202108940R A SG 11202108940RA SG 11202108940R A SG11202108940R A SG 11202108940RA
- Authority
- SG
- Singapore
- Prior art keywords
- same
- derivative compound
- heterotricyclic
- novel
- novel heterotricyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190019544A KR20200101219A (en) | 2019-02-19 | 2019-02-19 | Novel heterotricyclic derivatives and use thereof |
| PCT/KR2020/002427 WO2020171606A1 (en) | 2019-02-19 | 2020-02-19 | Novel heterotricyclic derivative compound and use of same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108940RA true SG11202108940RA (en) | 2021-09-29 |
Family
ID=72144293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108940RA SG11202108940RA (en) | 2019-02-19 | 2020-02-19 | Novel heterotricyclic derivative compound and use of same |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220135582A1 (en) |
| EP (1) | EP3929199A4 (en) |
| JP (1) | JP7358491B2 (en) |
| KR (1) | KR20200101219A (en) |
| CN (1) | CN113423710B (en) |
| AU (1) | AU2020226042B2 (en) |
| BR (1) | BR112021016448A2 (en) |
| CA (1) | CA3130456C (en) |
| CL (1) | CL2021002165A1 (en) |
| EA (1) | EA202191991A1 (en) |
| IL (1) | IL285604A (en) |
| MX (1) | MX2021009854A (en) |
| PE (1) | PE20211703A1 (en) |
| SG (1) | SG11202108940RA (en) |
| TW (1) | TWI829869B (en) |
| WO (1) | WO2020171606A1 (en) |
| ZA (1) | ZA202105970B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PE20230732A1 (en) | 2020-08-13 | 2023-05-03 | Hanmi Pharmaceutical Co Ltd | NOVEL DIOXOLISOQUINOLINONE DERIVATIVES AND USE THEREOF |
| KR102386403B1 (en) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | Novel dioxoloisoquinolinone derivatives and use thereof |
| WO2022179584A1 (en) * | 2021-02-26 | 2022-09-01 | 南京药石科技股份有限公司 | New ezh2 inhibitor and use thereof |
| WO2023217018A1 (en) * | 2022-05-07 | 2023-11-16 | 贝达药业股份有限公司 | Ezh2 inhibitor and use thereof in medicine |
| WO2023232025A1 (en) * | 2022-05-31 | 2023-12-07 | Hutchmed Limited | Tricyclic compounds and uses thereof |
| TW202415655A (en) | 2022-06-13 | 2024-04-16 | 美商樹線生物科學公司 | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
| CN115974856B (en) * | 2022-12-28 | 2023-08-11 | 北京康立生医药技术开发有限公司 | Preparation method of drug valmotustat for treating adult T-cell leukemia lymphoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| UA111305C2 (en) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Condensed with lactams of aryl and heteroaryl |
| US9822103B2 (en) * | 2013-11-22 | 2017-11-21 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| BR112016020621B1 (en) * | 2014-03-17 | 2022-06-07 | Daiichi Sankyo Company, Limited | Compound, pharmaceutical composition, ezh1 and/or ezh2 enzyme activity inhibitor, tumor therapeutic agent, and antitumor agent |
| WO2015193768A1 (en) * | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
| EP3521285A1 (en) * | 2014-06-17 | 2019-08-07 | Pfizer Inc | Substituted dihydroisoquinolinone compounds |
| US10308638B2 (en) | 2015-03-25 | 2019-06-04 | The Regents Of The University Of California | Selective alpha-7 nicotinic receptor agonists and methods for making and using them |
| CA3100977A1 (en) * | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PE20230732A1 (en) * | 2020-08-13 | 2023-05-03 | Hanmi Pharmaceutical Co Ltd | NOVEL DIOXOLISOQUINOLINONE DERIVATIVES AND USE THEREOF |
-
2019
- 2019-02-19 KR KR1020190019544A patent/KR20200101219A/en not_active Application Discontinuation
-
2020
- 2020-02-19 TW TW109105374A patent/TWI829869B/en active
- 2020-02-19 EA EA202191991A patent/EA202191991A1/en unknown
- 2020-02-19 SG SG11202108940RA patent/SG11202108940RA/en unknown
- 2020-02-19 JP JP2021548205A patent/JP7358491B2/en active Active
- 2020-02-19 US US17/431,933 patent/US20220135582A1/en active Pending
- 2020-02-19 PE PE2021001370A patent/PE20211703A1/en unknown
- 2020-02-19 CA CA3130456A patent/CA3130456C/en active Active
- 2020-02-19 AU AU2020226042A patent/AU2020226042B2/en active Active
- 2020-02-19 WO PCT/KR2020/002427 patent/WO2020171606A1/en unknown
- 2020-02-19 CN CN202080013624.0A patent/CN113423710B/en active Active
- 2020-02-19 BR BR112021016448A patent/BR112021016448A2/en unknown
- 2020-02-19 MX MX2021009854A patent/MX2021009854A/en unknown
- 2020-02-19 EP EP20759257.7A patent/EP3929199A4/en active Pending
-
2021
- 2021-08-14 IL IL285604A patent/IL285604A/en unknown
- 2021-08-16 CL CL2021002165A patent/CL2021002165A1/en unknown
- 2021-08-19 ZA ZA2021/05970A patent/ZA202105970B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113423710A (en) | 2021-09-21 |
| CN113423710B (en) | 2024-06-14 |
| IL285604A (en) | 2021-09-30 |
| AU2020226042B2 (en) | 2022-07-14 |
| TW202045512A (en) | 2020-12-16 |
| ZA202105970B (en) | 2023-05-31 |
| PE20211703A1 (en) | 2021-09-01 |
| CA3130456C (en) | 2023-10-03 |
| CA3130456A1 (en) | 2020-08-27 |
| US20220135582A1 (en) | 2022-05-05 |
| EA202191991A1 (en) | 2021-12-10 |
| BR112021016448A2 (en) | 2021-11-09 |
| JP7358491B2 (en) | 2023-10-10 |
| TWI829869B (en) | 2024-01-21 |
| AU2020226042A1 (en) | 2021-09-09 |
| JP2022522648A (en) | 2022-04-20 |
| WO2020171606A1 (en) | 2020-08-27 |
| MX2021009854A (en) | 2021-09-28 |
| EP3929199A1 (en) | 2021-12-29 |
| KR20200101219A (en) | 2020-08-27 |
| CL2021002165A1 (en) | 2022-04-22 |
| EP3929199A4 (en) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202105970B (en) | Novel heterotricyclic derivative compound and use of same | |
| ZA202106304B (en) | Heterocyclic compound and use thereof | |
| EP3919483A4 (en) | Benzopyridone heterocyclic compound and use thereof | |
| EP3816153A4 (en) | Heterocyclic compound and use thereof | |
| EP3816154A4 (en) | Heterocyclic compound and application thereof | |
| EP3589319A4 (en) | Glycan-interacting compounds and methods of use | |
| EP3886853A4 (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL285117A (en) | Methods of characterizing condensate-associated characteristics of compounds and uses thereof | |
| EP3907225A4 (en) | Imidazopyridine derivative compounds and use of same | |
| IL276592A (en) | Derivatives of sobetirome | |
| EP3697791A4 (en) | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | |
| IL287026A (en) | Heterocyclic compounds and uses thereof | |
| IL286697A (en) | Neuregulin-4 compounds and methods of use | |
| IL276912A (en) | Heterocyclic compound and use thereof | |
| SG11202101308QA (en) | Novel magnesium-serinate compound and use thereof | |
| EP3915638A4 (en) | Heterocyclic compound and use thereof | |
| EP3740468A4 (en) | Substituted aminopyrimidine compounds and methods of use | |
| EP3738961A4 (en) | Heterocyclic compound as csf-1r inhibitor and use thereof | |
| IL289336A (en) | Compounds and methods of use thereof as antibacterial agents | |
| GB2589398B (en) | Compounds and methods of use | |
| EP3476227A4 (en) | Composition for browning inhibition and use of same | |
| ZA202105399B (en) | Use of spiropidion | |
| EP3976039A4 (en) | Bisaminoquinolines and bisaminoacridines compounds and methods of their use | |
| EP4007497A4 (en) | ß-ARRESTIN-MODULATING COMPOUNDS AND METHODS OF USING SAME | |
| EP3790559A4 (en) | Photodynamic compositions and methods of use |